In fact, in different viral infection models like H1N1 influenza and respiratory syncytial virus, the knockout of IL-17 in murine models or the inhibition of IL-17 by monoclonal antibodies in humans has been linked to improved infection recovery and mitigation of related sequelae (51–53). Here, IL17A is linked to viral infectious disease.